Takeda

For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation. Today, our organization spans the globe—colleagues across business units and functions face challenges head-on to deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.

As a values-based, R&D-driven biopharmaceutical leader headquartered in Japan, we focus our R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. In addition to our R&D efforts, we’re laser-focused on harnessing the power of data, digital, and technology to improve health outcomes for patients across the globe.

Since our founding in Japan, integrity and putting patients first have been at the heart of our identity. We’re proud of our employees and their commitment to improving the quality of life for patients, and to working with our partners in health care in approximately 80 countries and regions. With each new breakthrough comes opportunities to develop your career, hone new skills, and create a brighter future.

For more information, visit https://jobs.takeda.com/

650 East Kendall Street Cambridge MA 02421 US
  • Featured Employer Badge
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • Takeda Top Global Employer 2024
  • Takeda LinkedIn Top 2024.png
  • 2025BPTW_GeneralBadge_FullColor.png
  • Takeda Disability Equality 2024
  • Takeda BGH 2024.png
CULTURE

At Takeda, we share a vision for the future where health care is more accessible, inclusive, sustainable, and affordable for all. And we believe our people are our greatest promise for delivering it. Individually, from R&D to IT, Finance to Maintenance, and every department in between, each of us brings the expertise, dedication, passion, and courage it takes to make history every day and change health care forever.

We’re grounded in over 240 years of history and are inspired each and every day by the possibility our future holds. Since our founding in Japan in 1781, integrity and putting patients first have been at the heart of our identity. These principles are ingrained in our culture and inspire our vision for the future. Our founding values remain core to our culture today and will inspire ideas that help you create a better tomorrow.

Across all parts of the business and corners of the world, our values unite and guide us. Our values are more than words on a page. They guide everything we do, uniting our teams across the world and lead us into the future. Our teams span the globe and work across a broad range of therapeutic areas, but we are connected by a shared values system. Bring your collaborative mindset and commitment and help us deliver the vision.

We’re dedicated to patients, our people, and the planet and proud of the contributions made by all our employees to drive impact. Each person’s contributions help us do better for patients, our fellow colleagues, and the planet. Take pride in knowing you help create a brighter future for patients, people, and the planet.

We’re constantly evolving—acting with endurance in our steadfast pursuit to achieve the best outcomes for our patients. We’re future-focused, delivering life-changing treatments through innovation. The drive to do better for patients means we are continuously evolving as a company and within our individual roles. Pursue new possibilities for patients while discovering new opportunities to grow your career.

DIVERSITY, EQUITY & INCLUSION

Across Takeda, we embrace and celebrate diversity, while striving to give patients and our people equitable access to opportunities that help them achieve their full potential. We take a values-based approach to inclusive patient experiences, inclusive work environments, workforce diversity and sustainable societal impact. We believe that diverse perspectives and experiences are key drivers of innovation. This starts with fostering an environment that creates a sense of belonging, allowing not only for everyone to have a voice, but a voice that is heard and valued.

NEWS
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
FDA
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
Acting on an option out of 2016 collaboration deal, Japan’s Takeda Pharmaceutical licensed Humabodies directed to one of its oncology targets from Cambridge, UK’s Crescendo Biologics.
Shares of Denali Therapeutics are up more than 10 percent in premarket trading after the company announced it has inked a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases.
As the acquisition of Shire by Takeda Pharmaceutical inches forward, global regulatory agencies are signing off on the deal. As the European Commission (EC) conducts a review of the deal, it hit a snag.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Two years after forging a partnership to collaborate on microbiome targets for gastrointestinal disorders, France-based Enterome SA and Takeda Pharmaceuticals have entered into a second agreement. This time with a specific focus on Crohn’s disease.
It has been six years since Johnson & Johnson first launched its JLABS incubators for the life science industry with a vision of providing assistance to startups that could potentially bring about a new paradigm of care for patients.
New late-stage data released by Janssen shows that a single dose of Stelara can induce clinical reemission and response in adult patients with moderate to severe ulcerative colitis who have not had positive response from previous treatment options.
JOBS
IN THE PRESS